Scott Schoenhaus
Stock Analyst at Keybanc
(1.88)
# 1,913
Out of 4,667 analysts
78
Total ratings
33.82%
Success rate
-9.44%
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALIT Alight | Maintains: Overweight | $10 → $11 | $7.84 | +40.40% | 6 | Nov 13, 2024 | |
| DOCS Doximity | Upgrades: Overweight | $70 | $48.81 | +43.43% | 1 | Nov 8, 2024 | |
| SLP Simulations Plus | Initiates: Overweight | $47 | $28.31 | +66.02% | 1 | Jul 29, 2024 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $7 → $5 | $2.69 | +85.87% | 3 | Jul 11, 2024 | |
| ABSI Absci | Maintains: Overweight | $8 → $6 | $2.59 | +132.11% | 4 | Jul 11, 2024 | |
| CERT Certara | Maintains: Overweight | $23 → $20 | $9.50 | +110.53% | 3 | Jul 11, 2024 | |
| LFMD LifeMD | Maintains: Overweight | $12 → $10 | $5.60 | +78.73% | 2 | Jul 11, 2024 | |
| PHR Phreesia | Maintains: Overweight | $27 → $25 | $18.54 | +34.84% | 5 | Jul 11, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $16 → $12 | $5.69 | +111.08% | 5 | Jul 11, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $30 → $25 | $19.00 | +31.61% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $100 | $102.96 | -2.87% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $14.42 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $7.54 | - | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $4.26 | +111.27% | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $232 → $250 | $213.53 | +17.08% | 14 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $43.03 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $41.97 | +42.96% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $9.68 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $194.62 | +28.46% | 2 | Apr 16, 2021 |
Alight
Nov 13, 2024
Maintains: Overweight
Price Target: $10 → $11
Current: $7.84
Upside: +40.40%
Doximity
Nov 8, 2024
Upgrades: Overweight
Price Target: $70
Current: $48.81
Upside: +43.43%
Simulations Plus
Jul 29, 2024
Initiates: Overweight
Price Target: $47
Current: $28.31
Upside: +66.02%
AbCellera Biologics
Jul 11, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $2.69
Upside: +85.87%
Absci
Jul 11, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.59
Upside: +132.11%
Certara
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $9.50
Upside: +110.53%
LifeMD
Jul 11, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $5.60
Upside: +78.73%
Phreesia
Jul 11, 2024
Maintains: Overweight
Price Target: $27 → $25
Current: $18.54
Upside: +34.84%
Recursion Pharmaceuticals
Jul 11, 2024
Maintains: Overweight
Price Target: $16 → $12
Current: $5.69
Upside: +111.08%
Schrödinger
Jul 11, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $19.00
Upside: +31.61%
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $102.96
Upside: -2.87%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $14.42
Upside: -
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $7.54
Upside: -
Apr 10, 2024
Upgrades: Overweight
Price Target: $9
Current: $4.26
Upside: +111.27%
Mar 5, 2024
Maintains: Overweight
Price Target: $232 → $250
Current: $213.53
Upside: +17.08%
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $43.03
Upside: -
Aug 15, 2023
Initiates: Overweight
Price Target: $60
Current: $41.97
Upside: +42.96%
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.68
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $194.62
Upside: +28.46%